Eribulin
- Generic Name
- Eribulin
- Brand Names
- Halaven, Eribulin Baxter, Mevlyq
- Drug Type
- Small Molecule
- Chemical Formula
- C40H59NO11
- CAS Number
- 253128-41-5
- Unique Ingredient Identifier
- LR24G6354G
- Background
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors .
- Indication
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
- Associated Conditions
- Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 27
- Registration Number
- NCT05063786
- Locations
- 🇪🇸
Hospital Galdakao-Usansolo, Bilbao, Spain
🇦🇹Ordensklinikum Linz GmbH - BHS, Linz, Austria
🇦🇹Pyhrn - Eisenwurzen Klinikum Steyr, Steyr, Austria
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
- Conditions
- Breast Inflammatory CarcinomaRecurrent Breast Inflammatory CarcinomaStage IV Breast Inflammatory Carcinoma
- Interventions
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT05041101
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer
- Conditions
- Breast Cancer FemaleNeoplasm, BreastBreast Cancer Metastatic
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Institut fuer Frauengesundheit
- Target Recruit Count
- 82
- Registration Number
- NCT05033769
- Locations
- 🇩🇪
Department of Gynecology, Tübingen University Hospital, Tübingen, Baden-Württemberg, Germany
🇩🇪Department of Gynecology and Obstetrics, Erlangen University Hospital, Erlangen, Bavaria, Germany
Scalp Cooling in MBC
- Conditions
- Chemotherapy-induced AlopeciaMetastatic Breast Cancer
- Interventions
- Device: Paxman Scalp Cooling System
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 120
- Registration Number
- NCT04986579
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2021-06-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 265
- Registration Number
- NCT04913571
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- MedSIR
- Registration Number
- NCT04826016
Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Drug: Personalized treatment guided by mini-PDX and RNA sequencing
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT04745975
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2020-12-24
- Target Recruit Count
- 80
- Registration Number
- NCT04683445
- Locations
- 🇨🇳
Sun Yat Sen Memorial Hospital，Sun Yat sen University, Guangzhou, Guangdong, China
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2020-12-23
- Target Recruit Count
- 71
- Registration Number
- NCT04681911
- Locations
- 🇨🇳
Sun Yat Sen Memorial Hospital，Sun Yat sen University, Guangzhou, Guangdong, China
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 331
- Registration Number
- NCT04639986
- Locations
- 🇨🇳
Affiliated Tumor Hospital of Xinjiang Medical University, Ürümqi, China
🇰🇷Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.